RubrYc Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
733 Industrial Rd, San Carlos, Californi...Phone Number
(650) 771-5267Website
www.rubryc.comRevenue
$5.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About RubrYc Therapeutics
RubrYc Therapeutics, Inc., is a biotechnology company applying proprietary machine-learning and computational biology solutions to discover epitope-selective mono and bispecific antibodies. The company was founded in 2017 and is headquartered in San Carlos, California.Explore more
RubrYc Therapeutics Org Chart
HD
Senior Scientist Discovery Immunology
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is RubrYc Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if RubrYc Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if RubrYc Therapeutics is spiking on competitors!
RubrYc Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when RubrYc Therapeutics launches new products
Click to see if RubrYc Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at RubrYc Therapeutics
Earning: See what the market has to say on RubrYc Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once RubrYc Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined RubrYc Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to RubrYc Therapeutics
Compare insights from companies similar to RubrYc Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
RubrYc Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
RubrYc Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about RubrYc Therapeutics.
RubrYc Therapeutics financials insights
Gather financial insights about RubrYc Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$25M
RubrYc Therapeutics Tech Stack
A closer look at the technologies used by RubrYc Therapeutics
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Funding
New Hire
Executive Move
Executive Moves, New Hire
Funding
, a biotherapeutics company, recently secured $2.26 million in funding.
Funding
Executive Move
Partnership, Board of Directors
RubrYc Therapeutics News & Media
A RubrYc Therapeutics bejelentette A2 körös, elsőbbségi részvénykibocsátással megvalósuló tőkebevonásának lezárását, valamint az iBio, Inc.-kel való együttműködési és licencmegállapodás megkötését
SAN CARLOS, Kalifornia állam, USA--(BUSINESS WIRE)--A RubrYc Therapeutics, Inc. (a továbbiakban „RubrYc”) és az iBio, Inc. (a továbbiakban „iBio”) (NYSEA: IBIO) ma bejelentette a RubrYc A2 körös, elsőbbségi részvénykibocsátással megvalósuló tőkebevonásának lezárását, valamint a két cég közt a tőkebevonással kapcsolatosan létrejövő, epitópalapú antitestterápiák kutatására, fejlesztésére és kereskedelmi bevezetésére irányuló együttműködésre vonatkozó licenc- és együttműködési megállapodás megkötéSpolečnost RubrYc Therapeutics oznamuje financování prostřednictvím prioritních akcií série A2, spolupráci a licenci na RTX-003 se společností iBio, Inc.
San Carlos (USA)--(BUSINESS WIRE)--Společnost RubrYc Therapeutics, Inc. („RubrYc“) a iBio, Inc. („iBio“, NYSEA: IBIO) ve středu oznámily uzavření financování prostřednictvím prioritních akcií série A2 společnosti RubrYc a souvisejících licenčních a kooperačních smluv zaměřených na výzkum, vývoj a komercializaci protilátkové terapie cílené na epitopy. Touto transakcí se společnost iBio stává významným strategickým investorem díky své investici 7,5 milionu dolarů do prioritních akcií RubrYc sérieRubrYc Therapeutics ogłasza finansowanie za pomocą akcji uprzywilejowanych serii A2, współpracę oraz licencję na RTX-003 z iBio, Inc.
SAN CARLOS, Kalifornia--(BUSINESS WIRE)--RubrYc Therapeutics, Inc. („RubrYc”) oraz iBio, Inc. („iBio”, NYSEA: IBIO) ogłosiły dzisiaj zamknięcie finansowania za pomocą akcji uprzywilejowanych serii A2 RubrYc oraz towarzyszących mu umów licencyjnych i umów o współpracy, których celem jest prowadzenie badań, rozwój i komercjalizacja terapii przeciwciałami ukierunkowanymi na epitopy. Dzięki tej transakcji iBio stało się ważnym inwestorem strategicznym, przeznaczając 7,5 mln USD na akcje uprzywilejoRubrYc Therapeutics anuncia acuerdo de licencia RTX-003, colaboración y financiación de acciones preferentes con serie A2 con iBio, Inc.
SAN CARLOS, California--(BUSINESS WIRE)--RubrYc Therapeutics, Inc. (“RubrYc”) e iBio, Inc. (“iBio”, NYSEA: IBIO) anunciaron hoy el cierre de financiación de acciones preferentes con serie A2 de RubrYc y acuerdos de colaboración y de licencia concomitantes dirigidos a la investigación, el desarrollo y la comercialización de terapias de anticuerpos dirigidos a epítopos. Con esta transacción, iBio se convierte en un importante inversor estratégico con su inversión de 7,5 millones de USD en accione
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RubrYc Therapeutics
Sign Up For FreeTo access detailed company insights
RubrYc Therapeutics, Inc., is a biotechnology company applying proprietary machine-learning and computational biology solutions to discover epitope-selective mono and bispecific antibodies. The company was founded in 2017 and is headquartered in San Carlos, California.... Read More
